Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year Q3 revenue decrease.
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year Q3 revenue decrease.
August 09, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Arrowhead Pharmaceuticals shares are trading lower due to disappointing Q3 EPS results and a year-over-year revenue decrease.
The company's worse-than-expected Q3 EPS results and a year-over-year revenue decrease are likely to negatively impact investor sentiment and drive the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100